Listed by the USPTO as WEDDINGTON, KEVIN E
Tech Center 1600 • Art Units: 1613 1614 1621 1629
This examiner grants 75% of resolved cases
Kevin E. Weddington is assigned to USPTO Tech Center 1600 and Art Unit 1613. His record includes 1477 resolved cases, an allowance rate of 75.4%, and a median of 903 days to allowance. The interview lift is 9.7%, so the recorded association between interviews and allowance is positive but limited relative to the overall allowance result.
The principal companies shown are Deciphera Pharmaceuticals LLC, Antecip Bioventures Ii LLC, and Mindset Pharma Inc. The leading firms are COOLEY LLP, Baker, Donelson, Bearman, Caldwell & Berkowitz, PC, and BakerHostetler. This combination of substantial case volume and a positive interview association may help practitioners frame prosecution planning for matters assigned to this examiner.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 19684927 | BUPROPION AS A MODULATOR OF DRUG ACTIVITY | Non-Final OA | ANTECIP BIOVENTURES II LLC |
| 18591870 | POLYAMINO IODINATED COMPOUNDS AND RADIOPAQUE HYDROGELS FORMED THEREFROM | Final Rejection | Boston Scientific Scimed, Inc. |
| 18683842 | INDOLE DERIVATIVES AS SEROTONERGIC AGENTS USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | Non-Final OA | Mindset Pharma Inc. |
| 18700358 | IMIDAZO[1,2-A]PYRIDINE DERIVATIVES | Non-Final OA | SYNGENTA CROP PROTECTION AG |
| 18970577 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF GLIOBLASTOMA WITH A DUAL TARGETING ANTI-TUMOR COMPOSITION | Non-Final OA | Northwestern University |
| 18043436 | N-Linked Glycosylation Inhibitors and Methods of Using Same | Non-Final OA | YALE UNIVERSITY |
| 18892030 | EFFECTIVE TREATMENT OF DEPRESSION IN PATIENTS HAVING IMPAIRED LEARNING AND/OR MEMORY OR CERTAIN EEG CHARACTERISTICS WITH A BENZYLPIPERAZINE-AMINOPYRIDINE AGENT | Non-Final OA | Alto Neuroscience, Inc. |
| 18843652 | METHOD FOR PREVENTING OR TREATING HEARING LOSS | Non-Final OA | MACKAY MEDICAL COLLEGE |
| 17482364 | Post Cov19 Vaccine Remedies | Non-Final OA | IPRX, LLC |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy75.4% of resolved applications examined by Kevin E Weddington were allowed (1,477 resolved cases), compared with 33.8% across Art Unit 1613 over the last five years.
This examiner's interview lift is +9.7 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Kevin E Weddington took 903 days on average from filing to allowance.
Kevin E Weddington examines applications in Art Unit 1613 in Tech Center 1600 (Biotechnology & Pharmaceuticals).